<DOC>
	<DOC>NCT02073929</DOC>
	<brief_summary>Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease. The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS. 70 women will be included in af RCT. Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.</brief_summary>
	<brief_title>LIPT - Liraglutide in Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>PCOS &gt;18 years premenopausal BMI &gt;25 og 25 and thereunder + insulin resistent Exclusion Criteria (including): actualt or intended pregnancy inadeqvat contraception hormonal contraception within 6 weeks metfoomin, GLP1analog or DPP IV inhibitor within 3 months medications affectiv hemostatic mechanisme diabetes or other severe comorbidity familar MEN</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>